Nanobac Inc: Nano - Biofuels - FuelCells - NASA - 500 Beiträge pro Seite

[lifa]

RB: "Nanobac and Energy Production. This is fabulous news. They have the patents!"

Drüben gehts schon los, 0,06 $
http://www.advfn.com/p.php?pid=staticchart&s=NB^nnbp&p=0&t=1…

Nanobac Pharmaceuticals Inc (NNBP)
In Berlin und Frankfurt unter WKN: 912641

Press Release Source: U.S. Sustainable Energy Corp
U.S. Sustainable Energy Corporation and Nanobac Pharmaceuticals, Inc. Investigate Nanobacteria Link to Energy Production
Tuesday April 18, 2:13 pm ET


TAMPA, FL--(MARKET WIRE)--Apr 18, 2006 --
U.S. Sustainable Energy Corporation ("U.S. Sustainable" or "the Company") announced today that it is investigating and conducting joint research with Nanobac Pharmaceuticals, Inc. ("Nanobac") (OTC BB:NNBP.OB - News) on a possible connection between nanobacteria, or calcifying nano-particles, and its proprietary process for the production of biofuels from various biomass feedstocks using the Company's technologies....

http://biz.yahoo.com/iw/060418/0123621.html

200 Tagelinie wird heute genommen, dann geht es North to Alska !

[Montypower]

ich denke eher zum Südpol

[lifa]

Antwort auf Beitrag Nr.: 21.240.649 von Montypower am 19.04.06 15:54:18

Wir werden sehen, Monty, davon lebt die Börse...

Gehört zwar nicht hierher, aber es gibt News bei EFSF:

eFoodSafety.com Inc. Subsidiary Knock-Out Technologies Ltd. Files for Patent Protection on Bird Flu Formulas
http://biz.yahoo.com/bw/060419/20060419005248.html?.v=1

[mfierke]

[lifa]

Antwort auf Beitrag Nr.: 21.321.340 von mfierke am 25.04.06 22:39:35

...und Moni, hast du zugegriffen ? 28% sind für den Anfang gar nicht so schlecht...

[lifa]

Hallo, sonst noch wer an Bord ?

[hala]

Ja ich!

hala

[lifa]

Antwort auf Beitrag Nr.: 21.421.078 von hala am 03.05.06 19:33:36

Hi hala,
ein Nick der ersten Stunde

In D ist (noch) nicht so viel los mit NNBP, aber hier steckt ´ne Menge Power drin, der Chart sieht astrein aus:

[lifa]

Zeit ist der Freund von wunderbaren Unternehmen und der Feind von mittelmäßigen Unternehmen.

Warren Buffett

[FlopBOB]

Mal wieder News:

Nanobac Pharmaceuticals and Fetzer Memorial Trust Enter Groundbreaking Collaboration to Photograph Never before Seen Calcification Mechanism

TAMPA, Fla., Aug 08, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals, Inc. (NNBP) ("Nanobac" or "the Company") today announced it has entered into a collaboration agreement with the Fetzer Memorial Trust to photograph the replication cycle of disease-related calcifying particles (also known as nanobacteria or Calcifying Nanoparticles), using light microscopes to break the 200 nanometer ("nm") resolution barrier. The breakthrough allows Nanobac scientists to determine if calcification, which occurs in most diseases on the leading causes of death list, has a biological mechanism, which would make it susceptible to therapy. Results could generate new approaches to the treatment of calcifying diseases such as heart disease, kidney stones and diabetes, and validate the significance of related Nanobac diagnostics and therapies.

"Until now, scientists had to 'fix' or inactivate such nanoparticles to see below the 200 nm threshold using electron microscopy," explained Nanobac's Co-Chairman and Research Group head, Dr. Benedict Maniscalco. "Now we can photograph the replication cycle without inactivating the particles. This is essential because some have a replication time of days rather than minutes or hours, which rendered electron microscopy ineffective for this purpose."

The technology was developed at Auburn University and is marketed by Aetos Technologies. The "CytoViva"(TM) microscope system is capable of resolving details at or below 100 nm and of detecting particles as small as 50 nm, representing a significant improvement over conventional light microscopes. The CytoViva(TM) system was selected in June by R&D Magazine as one of the top 100 most technologically significant products introduced to the marketplace in 2006. This international award is often referred to as the 'Oscar of Inventions.'

Calcifying nanoparticles have been isolated by many researchers in diseases ranging from atherosclerosis to kidney stones, but support for research into therapies against these particles has been hampered by lack of visual proof that the particles self-replicate. "Since the 1980s scientists have tried to photograph replication of calcifying nanoparticles, without success," Dr. Maniscalco added, "Now we have the tools to do it, thanks to the innovative approach of the Fetzer Memorial Trust."

The Fetzer Memorial Trust has supported development of this technology for many years, and has made arrangements for Nanobac to use one of a very few available microscopes. The research is being done by Nanobac scientists at Nanobac laboratories located at the NASA Johnson Space Center Astrobiology Laboratories in Houston, Texas, as part of Nanobac's recently announced new core research priorities. The microscope is currently located in Nanobac's labs and work has begun. Initial results are expected by year-end. Nanobac has the exclusive right to intellectual property resulting from discoveries about calcifying nanoparticles in this research project.

Quelle: http://bigcharts.marketwatch.com/news/articles.asp?guid={3EB…

Flop

[FlopBOB]

und noch mehr news

Nanobac Pharmaceuticals Inc. Announces Independent Study That Shows Nanobacteria Promote Gallstones
THURSDAY, AUGUST 10, 2006 9:57 AM

TAMPA, Fla., Aug 10, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals, Inc. (NNBP) ("Nanobac" or "the Company") today announced the publication by independent researchers of a proof of concept that calcifying nanoparticles, also known as nanobacteria, promote disease.

The company also announced it is initiating a project to validate the findings in its own experiments, to be completed by year-end 2006.

In "An Animal Model of Black Pigment Gallstones Caused by Nanobacteria" published in the June edition of the peer-reviewed journal Digestive Diseases and Sciences, Dr. Limin Wang et al from Shantou University Medical College, Guangdong, China, established that calcifying nanoparticles cause black pigment gallstones in rabbits when injected into the gallbladder. The study concludes, "We successfully cultured nano-sized particles coated with hydroxyapatite from human gallbladder bile and confirmed that they were nanobacteria by their typical growth rates, optical properties, specific stainability with Hoechst 33258, and by immunologic methods. By the animal experiment, we demonstrated for the first time that black pigment gallstones could be promoted by nanobacterial infection."

Previously no-one has shown a cause of black pigment gallstones. This type of gallstone accounts for 10-15 percent of all gallstones in humans and afflicts millions of people worldwide annually.

"This finding shows that calcifying particles provoke disease in an animal model," said Nanobac Co-Chairman Dr. Benedict Maniscalco. "It establishes these particles as infectious agents that are closely tied to calcification diseases which afflict tens of millions of people. The study leaves no doubt that these particles play a central role in disease and merit a broad investigation by the medical and scientific community," he added.

The study was conducted independent of Nanobac Pharmaceuticals and was not funded from any corporate source. The company has committed funding to a project to validate the study findings. Work is expected to begin this month and be completed by year-end 2006. Nanobac is the only company with regulatory approval of diagnostics that can accurately identify these calcifying particles. The company is also expecting to start a clinical trial on a promising therapy for such stone-forming diseases by the fourth quarter of 2006.

Abstract of the study is now available at PubMed by entering the study title at this website: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed

Quelle: http://bigcharts.marketwatch.com/news/articles.asp?guid={01A…

Flop

[FlopBOB]

Antwort auf Beitrag Nr.: 23.389.498 von FlopBOB am 10.08.06 19:03:45

so, n kleiner überblick von Nanobac

Nanobac Pharmaceuticals Inc. Announces Update for Shareholders and Interested Parties
WEDNESDAY, AUGUST 16, 2006 9:52 AM
- BusinessWire

TAMPA, Fla., Aug 16, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals Inc. (NNBP) ("Nanobac" or "The Company") today provided the following updates:

The Company recently filed its 10Q for the quarter ending June 30, 2006. Company CEO John Stanton stated, "I want to take this opportunity to highlight a few matters and set the course for future actions and expectations.

"As you're probably aware from recent news releases by Nanobac, the Company has sharpened its focus now that its intellectual property is consolidated and we are beginning to receive more results from our research.

"Cover stories in major news media have made it clear that inflammation and calcification are among the most prevalent and unsolved disease conditions on the 'leading causes of death list.' Inflammation and calcification occur in heart disease, breast cancer, and stone-forming diseases such as kidney stones and prostatitis.

"More than 20,000 published medical papers refer to calcification. Until now no one has identified a definite cause of the deposits, so imagine the impact on medicine of being able to show a cause, as well as the capability to diagnose and treat pathological calcification effectively.

"What has excited us at Nanobac recently is the independent findings published by scientists at well-known institutions, supporting what our own scientists have maintained for years: that the type of calcification generated by nanobacteria (Calcifying Nanoparticles or CNPs as they are also known) is a cause of inflammation, and a contributor to the damaging deposits found in those diseases.

"That is precisely our focus at Nanobac, and here are the main areas of our revitalized R&D program:

-- Therapy. The Company is entering into agreements to test its proprietary drug combination against stone-forming diseases, with a preliminary focus on prostatitis, which affects millions of men and is largely untreatable today, along with other stone forming diseases such as gallstones and kidney stones. Contracts have been entered into and we expect the first part of the trial to begin in the third quarter of 2006.

-- Proving Infection. The gold standard for proving that something is infectious is "Koch's postulates." In June of 2006, a new study published by independent scientists in a peer reviewed journal demonstrated key elements of Koch's postulates by showing that CNPs are implicated in formation of black pigment gallstones in an animal model. Until now there was no known cause of such gallstones that affect millions of persons. Nanobac is now entering into an agreement to validate this finding with the same scientists. Work will begin immediately. We are very excited about this landmark finding.

-- Identifying Infection Mechanisms. The Company has preliminary photographic and biochemical evidence that calcifying nanoparticles self-replicate, suggesting that they have a self-sustaining mechanism and might be infectious. In a new agreement with the Fetzer Memorial Trust, Nanobac recently began an experiment at its own laboratories at NASA in Houston to demonstrate this replication via time-lapse photography, using new award-winning CytoViva microscope technology capable of breaking through the 200 nanometer (nm) barrier for light microscopes. Our Scientific Director at the Johnson Space Center has very recently obtained proof of concept that this can be done, by taking preliminary photographs of CNPs at never-before-seen magnifications for real-time photography. Nanobac owns all IP arising from this particular experiment.

-- Thrombosis is the cause of death in most hemodialysis patients. The Company intends to validate its findings that calcifying nanoparticles discovered in human blood provoke thrombosis and might be preventable.

-- Diagnostics. The Company believes it has identified precisely what its proprietary Elisa antibody test is uniquely recognizing on calcifying nanoparticles, and has begun validating this finding.

"You can expect more information on these initiatives in the near future and results by early 2007.

"We have fortified our findings with patents to protect our exclusive capacities for diagnosis and therapy. The objection period for our nanobacteria eradication patent has expired without objections being filed, thus providing another valuable tool to turn our scientific findings into profits for our shareholders."

About Nanobac Pharmaceuticals

Nanobac Pharmaceuticals, Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate, and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting Calcifying Nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com .

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

Quelle:
Flop " target="_blank" rel="nofollow ugc noopener">http://bigcharts.marketwatch.com/news/articles.asp?guid={53532C01-7BEF-49FE-8B73-00ACB323A905}&newsid=880492048&symb=NNBP&sid=1501681

Flop " target="_blank" rel="nofollow ugc noopener">" target="_blank" rel="nofollow ugc noopener">http://bigcharts.marketwatch.com/news/articles.asp?guid={53532C01-7BEF-49FE-8B73-00ACB323A905}&newsid=880492048&symb=NNBP&sid=1501681

Flop

[FlopBOB]

Antwort auf Beitrag Nr.: 23.499.254 von FlopBOB am 18.08.06 17:19:24

Nanobac Pharmaceuticals Films Stunning Details of Nanoparticles Using New Technology
TUESDAY, AUGUST 22, 2006 12:26 PM

TAMPA, Fla., Aug 22, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals, Inc. (NNBP) ("Nanobac" or "the Company") today announced that its scientists have obtained new details about interactions of drugs with calcifying nanoparticles (CNPs), known also as nanobacteria, using award-winning light microscope technology.

The images show nanoparticles being affected by a therapeutic drug ingredient, and offer proof of concept that new microscope technology can detect real-time processes surrounding calcifying nanoparticles, which contain harmful calcifying constituents found in diseases such as kidney stones and atherosclerosis.

"This marks a watershed in the Company's ability to witness interactions between drug ingredients and calcifying nanoparticles," commented Nanobac Co-Chairman Dr. Benedict Maniscalco. "These images also demonstrate clear differences between CNPs and inorganic apatite, offering further proof that CNPs are distinct from inorganic apatite particles."

The video and still images were obtained by Nanobac scientists Dr. Neva Ciftcioglu and Grace Mathew at Nanobac laboratories in the NASA Johnson Space Center in Houston. The images will be released once the processes they recorded have been validated.

The success is an early result of a collaboration agreement between Nanobac and the Fetzer Memorial Trust to photograph the replication cycle of disease-related calcifying particles (also known as nanobacteria or Calcifying Nanoparticles), using light microscopes to break the 200 nanometer ("nm") resolution barrier. The breakthrough may allow Nanobac scientists to determine if calcification, which occurs in most diseases on the leading causes of death list, has a biological mechanism, which would make it susceptible to therapy.

Until now, scientists had to 'fix' or inactivate such nanoparticles to see below the 200 nm threshold using electron microscopy, which precluded observing real-time processes.

The "CytoViva"(TM) microscope system, developed at Auburn University and marketed by Aetos Technologies, can resolve details at or below 100 nm and detect particles as small as 50 nm, representing a significant improvement over conventional light microscopes. The CytoViva(TM) system was selected in June by R&D Magazine as one of the top 100 most technologically significant products introduced to the marketplace in 2006. The award is often referred to as the 'Oscar of Inventions.'

About Nanobac Pharmaceuticals

Nanobac Pharmaceuticals, Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate, and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting Calcifying Nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com

Flop

[Dersisco]

Antwort auf Beitrag Nr.: 23.563.496 von FlopBOB am 22.08.06 18:33:14

Tja, Ausbruch würde ich sagen.Altes Hoch bei 0,105 rausgenommen.Umsatz war Hölle.Sollte jetzt nach 0,20 steigen und zwar schnell
Gruß

[Dersisco]

Antwort auf Beitrag Nr.: 23.563.496 von FlopBOB am 22.08.06 18:33:14

Scheint noch jede Menge Luft nach oben!

[FlopBOB]

Antwort auf Beitrag Nr.: 23.576.760 von Dersisco am 23.08.06 13:39:34

Wegen mir können die gerne noch n bisschen weitersteigen

Wegen der hohen Umsätze denke ich mal, dass der H&A Nanofond evtl. seine Position ein bisschen aufgestockt hat aufgrund der letzen paar News. Ist aber, wie gesagt, nur ne Vermutung. Vielleicht hat jemand Lust da mal nachzuforschen, ich bin zu faul .


Nanobac Pharmaceuticals Inc. Announces Agreement to Validate Proof That Nanobacteria Promote Gallstones
WEDNESDAY, AUGUST 23, 2006 9:35 AM

TAMPA, Fla., Aug 23, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals, Inc. (NNBP) ("Nanobac" or "the Company") today announced that it has entered into an agreement and started work on an animal model to validate a proof of concept that calcifying nanoparticles (CNPs), also known as nanobacteria, promote gallstones.

If the proof is validated, it will solve the ages-old mystery of what provokes black pigment gallstones affecting millions of persons, and forge a path to effective early diagnosis and therapy where none are presently available. Results are expected by year-end 2006. Because these gallstones contain material similar to that in kidney stones and breast cancer calcifications, the results could apply to other unsolved calcification-related conditions as well.

The agreement was signed with the same scientific team who, in "An Animal Model of Black Pigment Gallstones Caused by Nanobacteria" published in the June 2006 edition of the peer-reviewed journal Digestive Diseases and Sciences, established that calcifying nanoparticles promote black pigment gallstones in rabbits when injected into the gallbladder.

The study concludes, "We successfully cultured nano-sized particles coated with hydroxyapatite from human gallbladder bile and confirmed that they were nanobacteria by their typical growth rates, optical properties, specific stainability with Hoechst 33258, and by immunologic methods. By the animal experiment, we demonstrated for the first time that black pigment gallstones could be promoted by nanobacterial infection."

The initial study was conducted independent of Nanobac Pharmaceuticals and was not funded from any corporate source. Abstract of that study is available at PubMed by entering the study title at this website: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed

The Principle Investigator is Dr. LiMin Wang, from Shantou University Medical College, Guangdong, China. Results will be verified by a team consisting of a former Merck executive and other U.S. experts in urology and infectious diseases.

Nanobac is the only Company with regulatory approval of diagnostics that can accurately identify these calcifying particles. The Company is also expecting to start a clinical trial on a promising therapy for such stone-forming diseases by the fourth quarter of 2006.

About Nanobac Pharmaceuticals

Nanobac Pharmaceuticals, Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate, and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting Calcifying Nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com .
Quelle:
http://bigcharts.marketwatch.com/news/articles.asp?guid={C45…

Flop

[hala]

Wall Street Resources, Inc. Releases an Analytical Profile on Nanobac Pharmaceuticals, Inc. with 12-Month Target Value of $0.91

Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") today announced the release of an analytical profile on the Company, by respected micro-cap analyst Mr. Paul Silver, Director of Research for Wall Street Resources, Inc., which contains a short-term target value for NNBP of $0.91 per share.

The free report is available at: http://www.wallstreetresources.net/pdf/fc/NNBP.pdf. The 31-page report includes detailed information on the Company's business model, products, industry, valuation, management and risks. Wall Street Resources, Inc. is a professional research and consulting firm with over 10 years of experience providing analysis for emerging growth companies and information to the investment community.

"We are very excited that Wall Street Resources has seen fit to issue an overall evaluation of our company, and with a short-term target value of $0.91 per share. Our management team and scientists have worked very hard to become the leader in Calcifying Nanoparticles (CNPs), and we consider this report to be verification that our management team is on track," stated John Stanton, CEO of Nanobac Pharmaceuticals. "The quality of Mr. Silver's research, coupled with the comprehensive analysis of our business plan, will assist the Company in gaining proper awareness among key decision makers in the market and help our investors and potential shareholders obtain a more thorough understanding of Nanobac Pharmceuticals, Inc." Mr. Silver stated, "Nanobac's extensive body of scientific research in the study of Calcifying Nanoparticles represents a paradigm shift in the understanding of calcific disease. We believe that Nanobac's developments of diagnostic and therapeutic products will revolutionize the medical industry. With the market for calcific diseases currently exceeding $500 billion per year, we believe that the commercial opportunities for Nanobac's products are virtually limitless."

[hala]

Wall Street Resources, Inc. Releases an Analytical Profile on Nanobac Pharmaceuticals, Inc. with 12-Month Target Value of $0.91

Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") today announced the release of an analytical profile on the Company, by respected micro-cap analyst Mr. Paul Silver, Director of Research for Wall Street Resources, Inc., which contains a short-term target value for NNBP of $0.91 per share.

The free report is available at: http://www.wallstreetresources.net/pdf/fc/NNBP.pdf. The 31-page report includes detailed information on the Company's business model, products, industry, valuation, management and risks. Wall Street Resources, Inc. is a professional research and consulting firm with over 10 years of experience providing analysis for emerging growth companies and information to the investment community.

"We are very excited that Wall Street Resources has seen fit to issue an overall evaluation of our company, and with a short-term target value of $0.91 per share. Our management team and scientists have worked very hard to become the leader in Calcifying Nanoparticles (CNPs), and we consider this report to be verification that our management team is on track," stated John Stanton, CEO of Nanobac Pharmaceuticals. "The quality of Mr. Silver's research, coupled with the comprehensive analysis of our business plan, will assist the Company in gaining proper awareness among key decision makers in the market and help our investors and potential shareholders obtain a more thorough understanding of Nanobac Pharmceuticals, Inc." Mr. Silver stated, "Nanobac's extensive body of scientific research in the study of Calcifying Nanoparticles represents a paradigm shift in the understanding of calcific disease. We believe that Nanobac's developments of diagnostic and therapeutic products will revolutionize the medical industry. With the market for calcific diseases currently exceeding $500 billion per year, we believe that the commercial opportunities for Nanobac's products are virtually limitless."

[FlopBOB]

Also bei $0.91, wäre der Laden ca. 180 Mio. $ Wert. Würden die nach Gold suchen, wären die schon nach den News im August so hoch bewertet worden .

Flop

[hala]

Das ist ja unglaublich schon wieder auf $ 0,28???
Scheint so als ob sie in einem Zug auf die $ 0,91 läuft, oder wer hat neue Infos ?

hala

[springbok]

Habe beim kaufen ein Problem.

Wollte 20000 St kaufen und das geht nur über Berlin und nicht über Frankfurt.

Habe mal die Salzgitter eingegeben und kein Problem mit den Börsenplätzen.

Wer hat das auch????

Gruss Springbok

[springbok]

Antwort auf Beitrag Nr.: 24.048.263 von springbok am 19.09.06 19:48:10

Hat keiner eine Antwort für mich---Dringend

Gruss Springbok

[gony2]

Antwort auf Beitrag Nr.: 24.052.235 von springbok am 19.09.06 23:29:05

Oh mein Gott was passiert hier? Keiner in Deutschland interresiert sich für die Aktie und sie steigt und steigt und schließt beim Tageshoch. hat denn keiner eine Erklärung dafür. Also der Handelsplatz in FFm hat gestern bei mir funktioniert.
PS meine Watchlist hat nun 811 %. .

[gony2]

++++++++++++++++45%

[gony2]

Antwort auf Beitrag Nr.: 24.055.269 von gony2 am 20.09.06 08:22:14

Erster Kursumsatz bei 30 Cent.

[Freddy123meins]

Antwort auf Beitrag Nr.: 24.055.959 von gony2 am 20.09.06 09:16:58

Völliger Blödsinn die Aktie jetzt zu kaufen da,

Kurs 0,30Cent
Bid 0,29
ASK 0,32
_____________

US Schlusskurs 0,35 US Dollar...

Ergo die Aktie is schon weit über Pari, Rat Finger davon lassen sowas geht ins Auge!

MFG
freddy123meins

[gony2]

Antwort auf Beitrag Nr.: 24.056.007 von Freddy123meins am 20.09.06 09:20:39

also für 32 würde ich auch nicht zuschalgen aber ich musste bis jetzt immer über pari kauef und habe es keine sekunde berreut.
ist schon komisch das der wert so markteng ist und der makler so damit rumspielt. aber ich werfe deshelb sicher keine weg. leider verhindert so eine taxe natürlich einen regen handel.

[Tanyildiz]

Ich beobachte die Aktie nun schon eine Woche und frage mich was hier los ist. In D sceint keiner diese Aktie so richtig zu kennen...

Lohnt sich der Einstieg noch?

Feedback bitte

Tany

[gony2]

Antwort auf Beitrag Nr.: 24.057.186 von Tanyildiz am 20.09.06 10:30:01

Hallo Tany, in D kennt keiner die Aktie und es inters. auch niemanden so richtig. Wohl deshalb auch weil es keine aktuellen News oder Veröffentlichungen gibt die diesen Anstieg begründen.
Abscheinend mausert sich Nanobac still und heimlich zu einer gestandenen Firma oder es ist was in der Pipeline was hier noch niemand weis. Einstieg jetzt ist schwierig denn Nanobac ist schon mehere Hundert Prozent gelaufen seit einer Woche. Auf der anderen Seite habe ich auch immer gedacht es wäre zu spät und nun habe ich immer mal wieder mitgekauft und lag damit wohl richtig. Muss jeder selbst entscheiden. Normalerweise kommt nach so einem brutalem Anstieg auch ein down aber schau dir doch mal die steigenden Umsätze jeden Tag an. 2,5 Mio Dollar bei einem so kleinen Wert Das sind doch keine Zocker, und das erkennt man daran das es jeden Tag nur up up geht. Gestern Schluss auf Tageshoch, das ist das beste Zeichen für einen weiteren Tag in grün.
Und wenn da noch eine News veröffentlicht wird...........oh mein Gott. Ich habe auch den Anstieg von Viropharma beobachtet und mir jeden tag gedacht, ach heute ist sie zu teuer. Ich habe einen Anstieg von 2 Euro auf 14 verpasst. Egal ich bin dabei und erwarte noch großes von Nanobac.

[Puhug]

Antwort auf Beitrag Nr.: 24.057.674 von gony2 am 20.09.06 10:56:18

der Anstieg wird einzig und allein auf die folgende und bereits mehrfach gepostete Meldung zurückzuführen sein und Kursziel 0,91 $ lockt eben an. Spätestens im Bereich 0,70 $ schätze ich, wird es wieder abwärts gehen.


Wall Street Resources, Inc. Releases an Analytical Profile on Nanobac Pharmaceuticals, Inc. with 12-Month Target Value of $0.91

TAMPA, Fla.--(BUSINESS WIRE)--Sept. 12, 2006--

Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) ("Nanobac" or "the Company") today announced the release of an analytical profile on the Company, by respected micro-cap analyst Mr. Paul Silver, Director of Research for Wall Street Resources, Inc., which contains a short-term target value for NNBP of $0.91 per share.

The free report is available at: http://www.wallstreetresources.net/pdf/fc/NNBP.pdf." target="_blank" rel="nofollow ugc noopener">http://www.wallstreetresources.net/pdf/fc/NNBP.pdf. The 31-page report includes detailed information on the Company's business model, products, industry, valuation, management and risks. Wall Street Resources, Inc. is a professional research and consulting firm with over 10 years of experience providing analysis for emerging growth companies and information to the investment community.

"We are very excited that Wall Street Resources has seen fit to issue an overall evaluation of our company, and with a short-term target value of $0.91 per share. Our management team and scientists have worked very hard to become the leader in Calcifying Nanoparticles (CNPs), and we consider this report to be verification that our management team is on track," stated John Stanton, CEO of Nanobac Pharmaceuticals. "The quality of Mr. Silver's research, coupled with the comprehensive analysis of our business plan, will assist the Company in gaining proper awareness among key decision makers in the market and help our investors and potential shareholders obtain a more thorough understanding of Nanobac Pharmceuticals, Inc."

Mr. Silver stated, "Nanobac's extensive body of scientific research in the study of Calcifying Nanoparticles represents a paradigm shift in the understanding of calcific disease. We believe that Nanobac's developments of diagnostic and therapeutic products will revolutionize the medical industry. With the market for calcific diseases currently exceeding $500 billion per year, we believe that the commercial opportunities for Nanobac's products are virtually limitless."

About Nanobac Pharmaceuticals

Nanobac Pharmaceuticals, Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate, and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting Calcifying Nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com .

About Wall Street Resources, Inc.:

Wall Street Resources, Inc. and its affiliated site http://www.wallstreetresources.net is a leading source for information on micro-to-small capital publicly traded companies. Wall Street Resources (WSR) acts as a conduit between micro-to-small capital company investors and emerging growth companies through its proprietary financial publications including daily and monthly newsletters, as well as comprehensive 20-50 page featured company reports. To sign up to receive WSR's financial publications go to: http://www.wallstreetresources.net/signup_promotion.asp. WSR also provides business consulting services to help corporate executives by writing analytical reports, building financial models, and developing business plans.

Disclaimer -- We, our affiliates, and any officer, director or stockholder or any member of their families may have a position in and may from time to time purchase or sell any securities discussed in our financial publications. There may be instances when fundamental, technical, and quantitative opinions may not be in concert. Our associates may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in our reports. WSR is a consultant to the Company and has received $15,000 in cash and 466,666 shares of 144 restricted stock for due diligence fees and consulting services from July of 2006 through February of 2007.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

Source: Nanobac Pharmaceuticals, Inc.

[gony2]

Antwort auf Beitrag Nr.: 24.059.745 von Puhug am 20.09.06 12:55:31

Niemals im Leben hat diese Studie was damit zu tun. Jede OTC Klitsche gibt sowas in Auftrag und zahl diese Studien auch selber. Sowas flatter jeden tag tausendfach über das Netz. Nene das sind andere Gründe. Ich glaube heute Mittag gegen 16-00 ist ein guter Einstiegszeitpunktpunkt denn der indikator steht auf rot.

[gony2]

Antwort auf Beitrag Nr.: 24.060.388 von gony2 am 20.09.06 13:31:24

Naja ich habe gerade den bericht gelesen. Nicht schlecht. Evtl doch der Auslöser des Anstiegs.

[gony2]

Antwort auf Beitrag Nr.: 24.060.626 von gony2 am 20.09.06 13:45:09

wow ist das spannend bis jetzt!
wir waren schon 15 % im minus.
war ja voaraus zu sehen und jetzt nur noch 5 %.
Mal schauen wohin die Reise heute geht.

[gony2]

Antwort auf Beitrag Nr.: 24.063.612 von gony2 am 20.09.06 16:01:52

jetzt rein denn wir sind bei minus 25 %

[gony2]

Antwort auf Beitrag Nr.: 24.064.032 von gony2 am 20.09.06 16:16:53

Nanobac Pharmaceuticals (OTCBB NNBP) Tuesday's market went up 45.83% to $0.35 per share, with a total of 8,541,820 shares traded. On Aug. 22, 2006, Nanobac Pharmaceuticals, Inc. announced that its scientists have obtained new details about interactions of drugs with calcifying nanoparticles (CNPs), known also as nanobacteria, using award-winning light microscope technology. "This marks a watershed in the Company's ability to witness interactions between drug ingredients and calcifying nanoparticles," commented Nanobac Co-Chairman Dr. Benedict Maniscalco. "These images also demonstrate clear differences between CNPs and inorganic apatite, offering further proof that CNPs are distinct from inorganic apatite particles."

Nanobac Pharmaceuticals, Incorporated, a bio-lifescience company, engages in the research and development of therapeutic and diagnostic technologies related to nanobacterium sanguineum. It also offers two diagnostic assays to identify the presence of Nanobacteria in blood, including NANO-CAPTURE for measuring levels of Nanobacterial antigen; and NANO-SERO for testing whether a patient has been exposed to Nanobacteria. Additionally, the company conducts biomedical research and clinical studies in the development of chronic prostatitis, kidney stones, and polycystic kidney diseases. Nanobac was co-founded by Neva Ciftcioglu in 1994. The company is headquartered in Tampa, Florida.

[gony2]

Antwort auf Beitrag Nr.: 24.064.190 von gony2 am 20.09.06 16:25:49

also -34 % hätte ich gestern nicht erwartet aber nach einem + von über 800 in ein paar wochen sind natürlich solche kursschwankungen auch mal drinnen und wie ich gestern schon schrieb war es im laufe des gestrigen tages absehbar. vom gefühl her würde ich sagen das die aktie heute nochmal ein minus von 15 % hinlegt um dann nächste woche wieder langsam aber sicher in die range von 30 cent zurückzukehren. Ich habe den vorstand von nanobac angeschrieben bezüglich anstehender projekte und news. sobald ich eine antwort habe, werde ich sie hier puplizieren.

[gony2]

Antwort auf Beitrag Nr.: 24.076.774 von gony2 am 21.09.06 09:13:40

http://www.advfn.com/p.php?pid=staticchart&s=NB^nnbp&p=0&t=1…

[SharpRatio]

Wall Street Resources, Inc. Releases an Analytical Profile on Nanobac Pharmaceuticals, Inc. with 12-Month Target Value of $0.91
Tuesday September 12, 8:01 am ET

TAMPA, Fla.--(BUSINESS WIRE)--Sept. 12, 2006--Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP - News; "Nanobac" or "the Company") today announced the release of an analytical profile on the Company, by respected micro-cap analyst Mr. Paul Silver, Director of Research for Wall Street Resources, Inc., which contains a short-term target value for NNBP of $0.91 per share.

ADVERTISEMENT
The free report is available at: http://www.wallstreetresources.net/pdf/fc/NNBP.pdf. The 31-page report includes detailed information on the Company's business model, products, industry, valuation, management and risks. Wall Street Resources, Inc. is a professional research and consulting firm with over 10 years of experience providing analysis for emerging growth companies and information to the investment community.

"We are very excited that Wall Street Resources has seen fit to issue an overall evaluation of our company, and with a short-term target value of $0.91 per share. Our management team and scientists have worked very hard to become the leader in Calcifying Nanoparticles (CNPs), and we consider this report to be verification that our management team is on track," stated John Stanton, CEO of Nanobac Pharmaceuticals. "The quality of Mr. Silver's research, coupled with the comprehensive analysis of our business plan, will assist the Company in gaining proper awareness among key decision makers in the market and help our investors and potential shareholders obtain a more thorough understanding of Nanobac Pharmceuticals, Inc."

Mr. Silver stated, "Nanobac's extensive body of scientific research in the study of Calcifying Nanoparticles represents a paradigm shift in the understanding of calcific disease. We believe that Nanobac's developments of diagnostic and therapeutic products will revolutionize the medical industry. With the market for calcific diseases currently exceeding $500 billion per year, we believe that the commercial opportunities for Nanobac's products are virtually limitless."

About Nanobac Pharmaceuticals

Nanobac Pharmaceuticals, Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate, and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting Calcifying Nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com .

[SharpRatio]

91 Cent Kursziel und dass noch kurzfristig. Locker bleiben.

[gony2]

Antwort auf Beitrag Nr.: 24.085.342 von SharpRatio am 21.09.06 16:27:20

easy bleiben, ganz genau. ich habe heute mal den ceo angeschrieben. mal schauen was nanobac so antwortet.

[springbok]

Ich glaube ich habe bei meinem Investment in die Nanobac etwas übersehen und das ist die Tatsache das man mit diesen Versuchen
Biofuel herstellen will.

Daran habe ich aber meine Zweifel ob das überhaupt gelingen kann.

Denn die Berichte im englichen sind reichlich verschraubt un d in einem Jahr wohl kaaum möglich.

Wer weiss denn mehr.

[springbok]

Antwort auf Beitrag Nr.: 24.093.824 von springbok am 21.09.06 23:50:14

Sorry Leute.ich habe mich durch den Namen des Threads irre führenlassen.

Habe alles nocch einmal durchgelesen und freue mich gekauft zu haben,noch was zu hoch,aber das legt sich auch wieder.

Dies ist eine wissenschaftliche Forschung auf dem Gebiet der Kalkabsetzung die im ganzen menschlichen Körper abläuft und zu den beschriebenen Krankheiten führt.

Sollte dort in den Jahren ein Durchbruch sich entwickeln,dann kann man nur den Kranken gratulieren das man diese Kalzifizierung beheben kann.

Was dies für den Kurs bedeutet muss sich jeder selber ausmalen.
Ich sehe Mierfke ist auch dabei,ich grüsse Dich.

Gruss Springbok

[gony2]

Antwort auf Beitrag Nr.: 24.094.057 von springbok am 22.09.06 00:22:17

Also ich habe mich auch kräftig mit Nanobac eingedeckt. Es gibt sehr viele Werte die Forschen und am Entwickeln sind und dementsprechend auch eine niedrige Marktkapitalisierung aufweisen. Aber irgendwann erwachen diese Werte aus ihrem Schlaf und finden durch ihre Ergebnisse internationale Anerkennung und generieren Geschäfte. Nanobac entwickelt keinen Biokraftstoff sondern beschäftigt sich mit ganz anderen Dingen. Leute lest mal den kostenlosen Report:

http://www.wallstreetresources.net/pdf/fc/NNBP.pdf

Hier stehen wir am Anfang einer Erfolgsgeschichte und selbst wenn sich der Kurs jetzt erst mal ein paar Wochen seitärts bewegt und hier viele zu teuer drinnen sind glaube ich das wir bald ganz andere Kurse sehen werden.
Auch die Homepage ist sehr interessant.

[SharpRatio]

Der Ausverkauf ist gestoppt. Entweder seitwärts oder hoch. Eins von beiden.

[gony2]

Antwort auf Beitrag Nr.: 24.110.941 von SharpRatio am 22.09.06 20:10:54

wow wie geil.
ich freu mich auf nächste woche

[SharpRatio]

Antwort auf Beitrag Nr.: 24.119.019 von gony2 am 23.09.06 07:28:30

Ich denke sehr gut zu wissen, wo das Teil hingeht. Leider gibt es keinen einzigen Thread der die ganzen Infos auf die erste Seite bringt. NNBP ist der hyper schlechthin. Nächste Woche sehen wir 40 Cent. Meine Meinung.

Teilweise sind die Threads auch irreführend. Bei einem heißt es Biodiesel. Völliger Blödsinn. Die sind im lukrativsten aller Gesundehitsmärkte aktiv und dass sind Herzkreislauferkrankungen.

[FlopBOB]

Da die anderen Threads, für mein Verständnis, zu unübersichtlich werden, werde ich in diesen Thread nur die News posten. Falls jemand etwas zum chart etc. ergänzen möchte, ohne in Pushermanier zu verfallen, ist er mir hier willkommen .

Nanobac Pharmaceuticals Inc. Launches Landmark Study to Explore Heart Disease Properties of Calcifying Nanoparticles
MONDAY, SEPTEMBER 25, 2006 8:00 AM

TAMPA, Fla., Sep 25, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals Inc. (OTCBB:NNBP - News; "Nanobac" or "the Company") and Mayo Clinic have reached an agreement to study whether calcifying nanoparticles, already found in atherosclerotic plaque, are infectious and contribute to the onset of heart disease.

The identification of the cause of calcification would be a landmark in heart disease research. While many pathogens have been identified as a possible cause of calcification in the blood vessels of heart disease patients, to date, no smoking gun has been identified.

The study, "Nanoparticles and Arterial Calcification," will be led by Virginia Miller, Ph.D., with John Lieske, M.D., and Franklin Cockerill, M.D., all of the Mayo Clinic. It is part of a multi-pronged initiative by scientists internationally to determine the disease-causing characteristics of calcifying nanoparticles (CNPs), known as nanobacteria(1). Each of the researchers has published work in peer-reviewed journals regarding the potential role of CNPs in heart disease.

"These Mayo Clinic researchers are among leading investigators into the disease-related aspects of CNPs," said Nanobac Pharmaceuticals' co-chair Dr. Benedict Maniscalco, himself a cardiologist who has published research in the field. "We have studied the process of calcification for years and have documented evidence that will set the course for this next phase of the research."

The study represents an acceleration of research into the infectious aspects of calcifying nanoparticles following findings published by other researchers earlier this year that CNPs provoke stone forming disease in an animal model. Other concurrent studies are occurring in China, Finland, and at world-class facilities in Cleveland, Washington D.C. and at Johnson Space Center in Houston. Those studies are directed at other disease-causing characteristics of CNPs and potential therapies.

Nanobac and Mayo Clinic have had a general collaboration agreement since 2005.

(1) (Note to editors: the term "Calcifying Nanoparticle (CNP)" has been adopted in recently published literature to help distinguish these particles from bacteria.)

About Nanobac Pharmaceuticals: Nanobac Pharmaceuticals Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria." The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

SOURCE: Nanobac Pharmaceuticals Inc.

Nanobac Pharmaceuticals Inc., Tampa
Douglas Mulhall, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348

Flop

[FlopBOB]

Antwort auf Beitrag Nr.: 21.240.300 von lifa am 19.04.06 15:39:18

Nanobac Pharmaceuticals Inc. Signs Agreement with American Health Associates Clinical Laboratories to Provide Calcifying Nanoparticle Tests in the United States
WEDNESDAY, OCTOBER 04, 2006 10:18 AM

TAMPA, Fla., Oct 04, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals Inc. (NNBP) ("Nanobac" or "the Company") and American Health Associates Clinical Laboratories (AHA) have reached an agreement for AHA to serve as the exclusive U.S. provider of Nanobac proprietary blood tests that can detect blood levels of Calcifying Nanoparticles (CNPs), which are found in coronary artery calcification, kidney stones, and other stone forming diseases. CNPs have been found in preliminary studies to be markers of arterial calcification, which in turn is a reliable marker of heart disease risk. AHA is a well-established certified laboratory headquartered in Miramar, Florida, and accepts blood samples from across the U.S.

"Nanobac has partnered with AHA for this important test so that our company can focus on its core R&D while continuing to make available and expanding the availability of these tests for research purposes," explained Nanobac Co-Chairman Dr. Benedict Maniscalco. "For the first time ever we now have a qualified laboratory in the U.S. where physicians can send blood samples for testing, along with authorized stations where patients can go to have blood drawn and know that the samples will be properly handled," Dr. Maniscalco added.

The tests can detect CNP antigens and antibodies. Analysis is done by Nanobac's own laboratories in Kuopio Finland; the only lab in the world capable of such analysis. Nanobac has performed thousands of such tests worldwide since the year 2000.

(a) (Note to editors: the term "Calcifying Nanoparticle (CNP)" has been adopted in recently published literature to help distinguish these particles from bacteria.)

About Nanobac Pharmaceuticals: Nanobac Pharmaceuticals Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria." The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

SOURCE: Nanobac Pharmaceuticals Inc.

Flop

[FlopBOB]

Antwort auf Beitrag Nr.: 21.240.300 von lifa am 19.04.06 15:39:18

Nanobac Pharmaceuticals Partners with Health Care Communications Firm

TAMPA, Fla., Oct 24, 2006 (BUSINESS WIRE) -- Nanobac Pharmaceuticals Inc. (NNBP) has enlisted The Aker Partners Inc. to implement a comprehensive national media relations program.

Nanobac is a growing pharmaceutical company in the field of medical nanotechnology. The company's focus is on developing methods to treat calcifying nanoparticles (CNPs), and by doing so, find more effective approaches to treating and preventing the cardiovascular, kidney and prostate diseases associated with them.

"Nanobac is deep into landmark medical research that we believe will redefine the way we view disease and change the way physicians approach the treatment of illnesses," said Nanobac Co-Chairman Dr. Benedict Maniscalco. "We believe utilizing the experienced professionals at The Aker Partners will not only increase the visibility of our work in the field of medical nanotechnology, but also enhance the viability of our company."

Nanotechnology is the realm of discovering and exploiting the special characteristics of materials at the atomic scale. A nanoparticle is generally considered to be anything less than 100 nanometers, or 100 billionths of a meter. If a one-meter ruler could be stretched from New York City to Los Angeles, a nanometer on that ruler would still be only the size of an aspirin.

The specialized type of medical nanotechnology being pursued by Nanobac aims to combat disease on that "nano" scale by detecting calcifying nanoparticles that straddle the 100 nanometer size line, ranging in diameter from 75 nm to more than 500 nm. Researchers believe these CNPs are the basic cause of a multitude of illnesses.

Based in Washington, D.C., The Aker Partners is a specialist in the health care industry and has broad experience in the rapidly growing field of medical nanotechnology. The agency has engineered successful communications campaigns for companies utilizing nanotechnology and is at the forefront of the effort to educate the public about the positive medical implications of the technology.

"Over the last 24 years our firm has helped more than 500 clients tell their compelling stories and communicate their accomplishments," said Aker Partners Manager Partner Colburn Aker. "The breakthroughs occurring at Nanobac are some of the most unique stories we have ever had the opportunity to help communicate."

Nanobac Pharmaceuticals:

Nanobac Pharmaceuticals Inc., based in Tampa, FL, is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in prostate, gall bladder and vascular disease. Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. For details visit http://www.nanobac.com.

Flop

[FlopBOB]

Antwort auf Beitrag Nr.: 24.849.385 von FlopBOB am 25.10.06 18:04:15

Diese News ist vorerst mit Vorsicht zu genießen, da die American Health Associates Clinical Laboratories (AHA) bisher noch nicht im Inernet gefunden werden konnten . Für Ergänzungen wäre ich dankbar.

Flop

[FlopBOB]

Nanobac Pharmaceuticals Releases New Portrait of Calcifying Nanoparticles, Related Announcement to Follow
THURSDAY, OCTOBER 26, 2006 9:50 AM

TAMPA, Fla., Oct 26, 2006 (BUSINESS WIRE) -- Scientists for Nanobac Pharmaceuticals Inc. (NNBP) ("Nanobac" or "the Company") have published a new outlook on the role of calcifying nanoparticles (CNPs) in diseases such as atherosclerosis and kidney stones, setting the groundwork for what company officials call a "significant" announcement next week.

Entitled "What are Calcifying Nanoparticles?" the document on the company's Web site provides, for the first time, investors and journalists with a clear picture of the state of science on CNPs, formerly known as nanobacteria, and summarizes the role CNPs play in one of the most pervasive medical conditions in existence: calcification of arteries and organs.

"We decided to publish this summary so journalists and investors could have a clear idea of what the particles are before we release research next week that will show surprising new results," explained Nanobac Co-Chair Dr. Benedict Maniscalco.

The summary was completed following a conference earlier this month at the University of Auburn, sponsored by the Fetzer Memorial Trust, a non-profit foundation dedicated to bringing leading edge technologies to the forefront.

"After a lot of probing questions from some of the leading scientists in their field, our organization was able to assemble a document that accurately describes the state of knowledge on what CNPs are, what they do to us, and why interest in this pathogen is growing," Dr. Maniscalco added.

For years scientists have been struggling to assemble a snapshot of the "state of knowledge" about CNPs. The document was assembled to fill that gap.

One of the issues raised about CNPs is whether they are any different from calcified crystals that are found in kidney stones and hardening of the arteries.

"Our announcement (including video evidence) next week will show there is a difference, and that difference will explain a lot about why present therapies against calcification have been ineffective," Maniscalco said.

"In preparation for that announcement, and because there have been debates over what the particles actually are, we decided to gather the state of knowledge to date for everybody to see and discuss," he concluded.

Final work is still being done on video microscopy evidence assembled by Nanobac scientists, in preparation for its release next week. The new summary document "What Are Calcifying Nanoparticles (CNPs)?" is available at http://www.nanobac.com/content/what-are-cnps.htm." target="_blank" rel="nofollow ugc noopener">http://www.nanobac.com/content/what-are-cnps.htm.

About Nanobac Pharmaceuticals: Nanobac Pharmaceuticals Inc. is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs), formerly known as nanobacteria. The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

Flop